Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of JNJ-64417184 with Itraconazole and Etravirine
NCT04208373Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JNJ-64417184 in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Analyte Concentration, Area Under the Concentration-time Curve from Time Zero to the Last Measurable Concentration and 1 more. Started Dec 2019; status: completed.
02
Drugs
JNJ-64417184
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04208373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04208373.